that even though microarrays have a long way to go, the road seems to be paved for the adoption of this technology for the detection of early biomarkers for disease and toxicity.I expect that in the coming year(s), the results of the MAQC consortium will make regulatory agencies such as the FDA consider microarray technology as mature, at least for certain types of diagnostic tests.